Dallas, Texas 04/29/2014 (FINANCIALSTRENDS) – Sangamo Biosciences, Inc.(NASDAQ:SGMO) is one of the several high profile biopharmaceutical concerns which is working relentlessly on developing therapeutic uses for a variety of immunodeficiency viruses as well as immune deficiency syndromes.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) has in the month of April been a witness to a spate of insider trading sessions. As usually follows, the spate of insider sales has also led to unsteady performance on the stock markets.
However, towards the end of April, the stock has been showing upward trends. The 52 week range for this stock in terms of prices is reportedly between $6.86 low and $24.69 high. The shares have also traded between the ranges of $12.72 low and $13.72 high in the past quarter.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) has a market capital of $895.62 million and at the start of the previous trading session, the stock opened at prices of $13.63. The EPS for the stock is -0.47. Outstanding shares for this stack are66.69 million. Beta is 1.67.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) has been researching as well as developing commercial quality drugs which are of the type of Zinc finger deoxyribonucleic acid, which has several engine able components. These include the ZFP nucleases as well as other proteins which are typically used to make changes to the DNA sequences in several types.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) proteins are also used to begin or turn-on genes as well as turn-off genes. Typically, this company is focused on the development of therapies as well as solutions which will offer a range of applications which are based on ZFN technologies. These are already being evaluated on a continual basis for the Phase 11 as well as the two Phase 1/Ii clinical trials. By October 2013, the new unit had begun production. The commercial availability of these immunodeficiency solutions are proving to be profitable for this company!